Go online to PeerView.com/SZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with immunotherapy, targeted agents, and chemo-free options for follicular lymphoma (FL)? Find out by accessing this activity, where an expert will interpret new evidence supporting the continued integration of bispecific antibodies, CAR-T cell therapy, EZH2 inhibitors, and PI3K inhibitors across multiple lines of therapy in relapsed/refractory FL. Throughout, the expert shares guidance on therapeutic sequencing, safety management, and the future use of innovative combination platforms. Don’t miss this important update from ASH! Upon completion of this activity, participants should be better able to: Summarize evidence surrounding targeted, epigenetic, and immunotherapy options for R/R FL; Integrate modern, evidence-based sequential treatment plans for R/R FL that include immunomodulatory drugs, targeted therapies, epigenetic agents, bispecific antibodies, and CAR-T constructs; and Manage the unique suite of adverse events associated with the use of novel therapeutics as sequential management options in R/R FL
PeerView Internal Medicine CME/CNE/CPE Audio Podcast